Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) saw a significant growth in short interest in November. As of November 15th, there was short interest totalling 900 shares, a growth of 28.6% from the October 31st total of 700 shares. Based on an average daily trading volume, of 17,800 shares, the short-interest ratio is currently 0.1 days.

Immatics Stock Performance

Shares of NASDAQ IMTXW traded up $0.10 during trading hours on Monday, hitting $0.50. 600 shares of the company traded hands, compared to its average volume of 11,307. The company’s 50 day moving average price is $1.23 and its 200 day moving average price is $2.29. Immatics has a 12 month low of $0.35 and a 12 month high of $4.14.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.